use of mutant alkyltransferases for gene therapy to protect from

Details use of mutant alkyltransferases for gene therapy to protect from use of mutant alkyltransferases for gene therapy to protect from

1996-03-25

1999-10-12

Campbell, Bruce R.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

514 44, 435455, 435325, 4353201, 435 695, 536 231, A01N 6300

Patent

active

059651261

ABSTRACT:
The present invention relates to methods of treating neoplastic disease whereby gene therapy treatments are employed in combination with a chemotherapy regime. A combinational therapy with anti-neoplastic alkylating agents will optimize host tumor sensitivity to these agents used alone or in combination with O.sup.6 -benzylguanine (BG) or a similar compound or compounds. Hematopoietic cells are infected with a transgene expressing a mutant AGT protein exhibiting DNA repair activity while imparting resistance to BG or a related compound. Introduction of the transduced hematopoietic cell population expressing the mutant AGT protein into the patient in tandem with the chemotherapeutic regime will substantially reduce myelosuppression traditionally associated with the administration of these anti-neoplastic drugs.

REFERENCES:
patent: 5091430 (1992-02-01), Moschel et al.
patent: 5352669 (1994-10-01), Moschel et al.
patent: 5358952 (1994-10-01), Moschel et al.
patent: 5637483 (1997-06-01), Dranoff et al.
Allay, et al., 1995, Blood 85 (11): 3342-3351.
Moritz, et al., 1995, Can. Res., 55: 2608-2614.
Dolan, et al., 1994, Can. Res. 54: 5123-5130.
Crone, et al., 1995, Carcinogenesis 16 (8): 1687-1692.
Crone and Pegg, 1993, Can. Res. 53: 4750-4753.
Crone, et al., 1994, Can Res. 54: 6221-6227.
Pegg, et al., 1995, Biochem. Pharmacol. 50 (8): 1141-1148.
Gerson, et al., 1994, Mutation Res. 307: 541-555.
Dolan, et al., Can. Chemother Pharmacol. 35: 121-126.
Brody and Crystal, 1994, Ann NY Acad. Sci. 716: 90-103.
Dunbar, et al., 1993, Hum. Gene Ther. 4: 205-22.
Hawley, 1994, Ann NY Acad. Sci. 716: 327-330.
Cassel, et al., 1993, Exp. Hematol. 21: 585-591.
Sekhar, et al., 1996, Hum Gene Ther. 7: 33-38.
Dunbar, et al., 1994, Ann NY Acad. Sci 716: 216-227.
Dick, et al., 1991, Blood 78 (3): 624-634.
Huber and Lazo, 1994, Ann NY Acad. Sci. 716: 1-11.
Kotani, et al., 1994, Hum. Gene Ther. 5: 19-28.
Harris, et al., 1995, Proc. Amer. Assoc. Can Res. 36: 419.
Larochelle et al. Nature Medicine, 1995, vol. 2, 12:1329-1337.
Morrison et al. Nature Medicine, 1995, vol. 2, 12:1282.
Beusechem et al. Human Gene Therapy 1996, 7:1649-1668.
Banerjee et al. Stem Cells 1994, 12:378-385.
Karlsson. Blood 1991, vol. 78, 10:2481-2491.
Dolan (Adv. Drug Delivery Rev., 1997, 26, 2, 3:105-118).
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495).
Mastrangelo et al. (Seminars in Oncology, vol. 23, No. 1:4-21, 1996).
Stein J., ed., 1993 in: Internal Medicine, 4th edition, Mosby Year Book, pp. 699-715.
Gerson et al., Proc. Amer. Assoc. Cancer Res., vol. 35, Mar. 1994, p. 699.
Ronald Crystal, Science, vol. 270, 1995, pp. 404-410.
Crone et al. (Cancer Res., 54, 6221-6227, 1994).
Reese et al. (Proc. Amer. Assoc. Cancer Res., vol. 37, Mar. 1996, p. 334).
Marathi et al. (Proc. Amer. Ass. Cancer Res., Mar. 1995, vol. 36, p. 419).
Huber et al. (Annals New York Aca. Sci., vol. 716, 1994:6-12).

Affiliated with

Also associated with

Rating

use of mutant alkyltransferases for gene therapy to protect from does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with use of mutant alkyltransferases for gene therapy to protect from, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and use of mutant alkyltransferases for gene therapy to protect from will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-649385